Loading
Prostate Cancer Diagnosis and Treatment · Journal article
Andrology and Genital Surgery · September 6, 2026
A consensus or society position rather than new primary data.
This narrative review proposes that benign prostatic hyperplasia should be reconceptualized as a systemic metabolic disease rather than solely a local prostatic disorder, with chronic inflammation, metabolic syndrome components, and microbiota dysfunction acting as independent drivers of disease progression and reduced treatment efficacy. The authors advocate for personalized therapy incorporating metabolic correction to improve outcomes, based on synthesis of epidemiological, clinical, and experimental evidence linking these mechanisms.
Narrative review. Patients with benign prostatic hyperplasia, with and without concurrent metabolic syndrome and chronic prostatitis. Domestic and foreign literature reviewed; geography of included studies not specified.
Presence of metabolic syndrome and chronic prostatitis is associated with more frequent BPH detection and marked disease progression Patients with BPH and concurrent metabolic syndrome show significant prostate volume increase, higher prostate-specific antigen levels, and accelerated annual gland volume increase compared with those without metabolic disorders Components of metabolic syndrome are independent risk factors for severe lower urinary tract symptoms
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider assessing and correcting metabolic abnormalities (obesity, insulin resistance, dyslipidemia, hypertension, androgen deficiency) in BPH patients to potentially improve treatment efficacy and slow disease progression. The review suggests a shift toward personalized, metabolically-informed management rather than standard hormonal or surgical approaches alone.
A narrative review synthesizing epidemiological, clinical, and experimental literature to propose a conceptual framework linking metabolic syndrome and chronic inflammation to BPH pathogenesis and treatment response.
As stated by the source record.
Clinicians should consider assessing and correcting metabolic abnormalities (obesity, insulin resistance, dyslipidemia, hypertension, androgen deficiency) in BPH patients to potentially improve treatment efficacy and slow disease progression. The review suggests a shift toward personalized, metabolically-informed management rather than standard hormonal or surgical approaches alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Benign prostatic hyperplasia (BPH) is one of the most common urological diseases leading to the development of lower urinary tract symptoms. Traditionally, the pathogenesis of BPH is associated with hormonal imbalance and the activity of 5-α-reductase, however, modern data indicate a significant role of chronic inflammation of the prostate gland, systemic metabolic disorders, combined by the concept of “metabolic syndrome”. The review of domestic and foreign scientific literature, including epidemiological, clinical and experimental studies on the relationship of BPH, is carried out./urinary tract symptoms, chronic prostatitis and metabolic syndrome (obesity, insulin resistance, dyslipidemia, hypertension, androgen deficiency). It has been established that the presence of metabolic syndrome and chronic prostatitis is associated with more frequent detection of BPH and marked disease progression. In patients with BPH on the background of metabolic syndrome, a significant increase in prostate volume, higher levels of prostate-specific antigen, and an accelerated annual increase in gland volume are recorded compared with patients without metabolic disorders. The components of metabolic syndrome are independent risk factors for severe urinary tract symptoms. The main pathogenetic mechanisms include chronic pelvic ischemia, hyperinsulinemia, imbalance of sex hormones and chronic sluggish inflammation. The effectiveness of drug and surgical treatment in this group of patients is reduced. Benign prostatic hyperplasia should be considered not as a local disease, but as a systemic metabolic disease of the age period. Various components of the metabolic syndrome and chronic inflammation of the gland independently accelerate the progression of BPH/urinary tract symptoms, which requires the personalization of therapy with mandatory correction of metabolic disorders to increase the effectiveness of treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.